Background The landmark study of durvalumab as consolidation therapy in NSCLC patients
(PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients …

Lung cancer is the leading cause of cancer-related deaths worldwide. Medical imaging
technologies such as computed tomography (CT) and positron emission tomography (PET) …

Tumor vasculature is a key component of the tumor microenvironment that can influence
tumor behavior and therapeutic resistance. We present a new imaging biomarker …

Purpose To develop a radiomics nomogram based on computed tomography (CT) to
estimate progression-free survival (PFS) in patients with small cell lung cancer (SCLC) and …

Purposes and Objectives The aim of this study was to predict the progression-free survival
(PFS) in patients with small cell lung cancer (SCLC) by radiomic signature from the contrast …

Background and objective For patients with advanced colorectal liver metastases (CRLMs)
receiving first-line anti-angiogenic therapy, an accurate, rapid and noninvasive indicator is …

The prognosis of extensive-stage small cell lung cancer is usually poor. In this study, a
combined model based on pre-treatment CT radiomics and clinical features was constructed …

Rationale and Objectives To evaluate the validity of CT-based delta radiomics signatures in
predicting overall survival (OS) and local recurrence (LR) in small cell lung cancer (SCLC) …

Objectives Metachronous liver metastasis (LM) significantly impacts the prognosis of stage I-
III colorectal cancer (CRC) patients. An effective biomarker to predict LM after surgery is …

Objectives To develop and validate a CT-based radiomics nomogram that can provide
individualized pretreatment prediction of the response to platinum treatment in small cell …